A detailed history of Capital Analysts, LLC transactions in Omeros Corp stock. As of the latest transaction made, Capital Analysts, LLC holds 1,000 shares of OMER stock, worth $7,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$7,590
Previous $4,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 05, 2021

SELL
$14.81 - $19.13 $14,810 - $19,130
-1,000 Reduced 50.0%
1,000 $15,000
Q1 2021

May 17, 2021

BUY
$14.52 - $23.53 $29,040 - $47,060
2,000 New
2,000 $36,000
Q4 2020

Feb 16, 2021

SELL
$10.14 - $15.19 $1.2 Million - $1.8 Million
-118,767 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$9.57 - $21.32 $427,798 - $953,046
44,702 Added 60.36%
118,767 $1.2 Million
Q2 2020

Aug 07, 2020

SELL
$12.21 - $16.99 $4,578 - $6,371
-375 Reduced 0.5%
74,065 $1.09 Million
Q1 2020

May 08, 2020

BUY
$9.03 - $19.72 $4,018 - $8,775
445 Added 0.6%
74,440 $995,000
Q4 2019

Feb 12, 2020

BUY
$13.01 - $17.15 $910 - $1,200
70 Added 0.09%
73,995 $1.04 Million
Q4 2018

Feb 13, 2019

BUY
$10.72 - $16.73 $124,888 - $194,904
11,650 Added 18.71%
73,925 $824,000
Q3 2018

Nov 07, 2018

BUY
$17.73 - $26.69 $10,638 - $16,014
600 Added 0.97%
62,275 $0
Q2 2018

Aug 03, 2018

SELL
$10.79 - $24.44 $2,967 - $6,721
-275 Reduced 0.44%
61,675 $0
Q1 2018

May 14, 2018

BUY
$9.0 - $20.16 $18,000 - $40,320
2,000 Added 3.34%
61,950 $692,000
Q4 2017

Feb 14, 2018

SELL
$13.26 - $22.86 $7.04 Million - $12.1 Million
-530,899 Reduced 89.85%
59,950 $1.17 Million
Q4 2017

Feb 12, 2018

BUY
$13.26 - $22.86 $7.04 Million - $12.1 Million
530,899 Added 885.57%
590,849 $36.1 Million
Q3 2017

Nov 06, 2017

BUY
$19.76 - $24.9 $1.18 Million - $1.49 Million
59,950
59,950 $1.3 Million

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $476M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Capital Analysts, LLC Portfolio

Follow Capital Analysts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Analysts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Analysts, LLC with notifications on news.